Highlights

• Mesoblast’s US-listed shares eased in Wednesday’s New York session, setting a softer tone for the cell therapy developer’s local stock. As Mesoblast continues operating within the ASX 200, growing attention is also being directed towards ASX Technical Analysis as companies across the sector navigate changing market conditions.
• As ASX futures and ASX live trading set the mood, Mesoblast remains on the radar for readers following the ASX index.
• The local shares have surrendered a large part of the sharp jump that followed the company’s quarterly update in late October.
• A modest bounce early this week has emerged from a support zone near the top of…